The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers
dc.contributor.author | Molchan, Susan E. | en_US |
dc.contributor.author | Mellow, Alan M. | en_US |
dc.contributor.author | Hill, James L. | en_US |
dc.contributor.author | Weingartner, Herbert J. | en_US |
dc.contributor.author | Martinez, Rick A. | en_US |
dc.contributor.author | Vitiello, Benedetto | en_US |
dc.contributor.author | Sunderland, Trey | en_US |
dc.date.accessioned | 2010-04-14T13:35:01Z | |
dc.date.available | 2010-04-14T13:35:01Z | |
dc.date.issued | 1992 | en_US |
dc.identifier.citation | Molchan, Susan; Mellow, Alan; Hill, James; Weingartner, Herbert; Martinez, Rick; Vitiello, Benedetto; Sunderland, Trey (1992). "The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers." Journal of Psychopharmacology 6(4): 489-500. <http://hdl.handle.net/2027.42/68371> | en_US |
dc.identifier.issn | 0269-8811 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/68371 | |
dc.description.abstract | Thyrotropin-releasing hormone (TRH), a neuromodulator and possibly a neurotransmitter in the central nervous system, was shown in a prior study of young normal volunteers to attenuate the memory impairment induced by the anticholinergic drug scopolamine. In the present study, the cognitive, behavioral and physiologic effects of high dose TRH (0.5 mg/kg), both alone and following administration of scopolamine, were examined in 10 Alzheimer's disease (AD) patients (mean age±SD=63.5 years) and 12 older normal volunteers (mean age=64.9±8.8 years). On the day AD subjects received TRH alone, modest but statistically significant improvement from baseline performance was documented on some tests of learning and memory, especially in those with mild dementia severity. In comparing cognitive test performance between the scopolamine alone and scopolamine+TRH conditions, only two test scores were significantly higher in the latter condition. In the group of older volunteers, TRH did not attenuate scopolamine-induced cognitive impairment, contrary to prior findings in a group of younger controls. In fact, older subjects performed worse after receiving scopolamine followed by TRH than after receiving scopolamine alone. In addition, no change from baseline cognitive performance was detected after subjects received TRH alone. These findings raise several questions and speculations on possible age-related changes in the cholinergic system, as well as on the mechanism of the interaction of TRH with the cholinergic system. | en_US |
dc.format.extent | 3108 bytes | |
dc.format.extent | 1102385 bytes | |
dc.format.mimetype | text/plain | |
dc.format.mimetype | application/pdf | |
dc.publisher | Sage Publications | en_US |
dc.subject.other | Thyrotropin-releasing Hormone (TRH) | en_US |
dc.subject.other | Neuropeptide | en_US |
dc.subject.other | Scopolamine | en_US |
dc.subject.other | Memory | en_US |
dc.subject.other | Alzheimer's Disease; Ageing | en_US |
dc.title | The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Psychiatry, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | Unit on Biostatistics, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | Section on Cognitive Neurosciences, National Instituteof Alcoholism and Alcohol Abuse, Bethesda, MD, USA | en_US |
dc.contributor.affiliationother | Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/68371/2/10.1177_026988119200600404.pdf | |
dc.identifier.doi | 10.1177/026988119200600404 | en_US |
dc.identifier.source | Journal of Psychopharmacology | en_US |
dc.identifier.citedreference | Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50: 1914-1923 | en_US |
dc.identifier.citedreference | Bartus R.T., Dean R.L., Beer B., Lippa A.S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-417 | en_US |
dc.identifier.citedreference | Bassiri R.M., Utiger R.D. (1973) Metabolism and excretion of exogenous thyrotropin releasing hormone in humans. J Clin Invest 52: 1616-1619 | en_US |
dc.identifier.citedreference | Battig W., Montague N. (1969) Category norms for verbal items in 56 categories. J Exp Psychol Monogr 80: 1-43 | en_US |
dc.identifier.citedreference | Behbehani M.M., Pun R Y K, Means E.D., Anderson D.K. (1990) Thyrotropin-releasing hormone has profound presynaptic action on cultured spinal cord neurons. Synapse 6: 169-174 | en_US |
dc.identifier.citedreference | Brandeis R., Dachir S., Sapir M., Levy A., Fisher A. (1990) Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B. Pharmacol Biochem Behav 36: 89-95 | en_US |
dc.identifier.citedreference | Breese G.R., Cott J.M., Cooper B.R., Prange A.J., Lipton M.A., Plotnikoff N.P. (1975) Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther 193: 11-22 | en_US |
dc.identifier.citedreference | Brezenoff H.E., Vargas H., Xiao Y-F. (1988) Blockade of brain M2 muscarinic receptors lowers blood pressure in spontaneously hypertensive rats. Pharmacology 36: 101-105 | en_US |
dc.identifier.citedreference | Burke R.E. (1986) The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes. Mov Disord 2: 135-144 | en_US |
dc.identifier.citedreference | Buschke H. (1973) Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 12: 543-550 | en_US |
dc.identifier.citedreference | Decker M.W. (1987) The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res Rev 12: 423-438 | en_US |
dc.identifier.citedreference | Drachman D.A., Leavitt J. (1974) Human memory and the cholinergic system. Arch Neurol 30: 113-121 | en_US |
dc.identifier.citedreference | Drachman D.A. (1977) Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 27: 783-790 | en_US |
dc.identifier.citedreference | Faden A.I., Jacobs T.P., Smith M.T. (1984) Thyrotropin-releasing hormone in experimental spinal injury: Dose response and late treatment. Neurology 34: 1280-1284 | en_US |
dc.identifier.citedreference | Gibson G., Peterson C., Jenden D.J. (1981) Brain acetylcholine declines with senescence. Science 213: 674-676 | en_US |
dc.identifier.citedreference | Griffiths E.C., Kelly J.A., Ashcroft A., Ward D.J., Robson B. (1989) Comparative metabolism and conformation of TRH and its analogues. Ann NY Acad Sci 5: 217-231 | en_US |
dc.identifier.citedreference | Hasher L., Zacks R.T. (1979) Automatic and effortful processes in memory. J Exp Psychol (Gen) 108: 356-388 | en_US |
dc.identifier.citedreference | Hefti F., Dravid A., Hartikka J. (1984) Chronic intraventricular injection of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septal-hippocampus lesions. Brain Res 293: 303-311 | en_US |
dc.identifier.citedreference | Horita A., Carino M.A., Lai H. (1986) Pharmacology of thyrotropin-releasing hormone. Annu Rev Pharmacol Toxicol 26: 311-332 | en_US |
dc.identifier.citedreference | Horita A., Carino M.A., Zabawska J., Lai H. (1989) TRH analog MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides 10: 121-124 | en_US |
dc.identifier.citedreference | Hutson P.H., Semark J.E., Middlemeiss D.N. (1990) The TRH analog MK-771 increases acetylcholine release in hippocampus but not striatum of the conscious rat. Neurosci Lett 116: 149-155 | en_US |
dc.identifier.citedreference | Lamour Y., Dutar P., Jobert A. (1983) Effects of neuropeptides on rat cortical neurons: laminar distribution and interaction with the effect of acetylcholine. Neuroscience 10: 107-117 | en_US |
dc.identifier.citedreference | Lamour Y., Senut M.C., Dutar P., Bassant M.H. (1989) Neuropeptides and septo-hippocampal neurons: Electrophysiological effects and distributions of immunoreactivity. Peptides 9: 1351-1359 | en_US |
dc.identifier.citedreference | Lampe T.H., Norris J., Risse S.C., Owen-Williams E., Keenan T. (1990) Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin co-administration in Alzheimer's disease. Neurobiol Aging 384: 346(Abstract) | en_US |
dc.identifier.citedreference | Lange K.W., Rossor M.N., Jenner P., Marsden C.D. (1990) Cholinergic markers in Alzheimer's disease and Parkinson's disease. Neurobiol Aging 384: 273(Abstract) | en_US |
dc.identifier.citedreference | Lippa A.S., Loullis C.C., Rotrosen J., Cordasco D.M., Critchett D.J., Joseph J.A. (1985) Conformational changes in muscarinic receptors may produce diminished cholinergic neurotransmission and memory deficits in aged rats. Neurobiol Aging 6: 317-323 | en_US |
dc.identifier.citedreference | Manaker S., Eichen A., Winokur A., Rhodes C.H., Rainbow T.C. (1986) Autographic localization of thyrotropin releasing hormone receptors in human brain. Neurology 36: 641-646 | en_US |
dc.identifier.citedreference | Marcyniuk B., Mann D M A, Yates P.O. (1989) The topography of nerve cell loss from the locus coeruleus in elderly persons. Neurobiol Aging 10: 5-9 | en_US |
dc.identifier.citedreference | Mash D.C., Flynn D.D., Potter L.T. (1985) Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228: 1115-1117 | en_US |
dc.identifier.citedreference | Mattila J., Bunag R.B. (1986) Sympathetic vasoconstrictor and renin secretion caused pressor responses to thyrotropin-releasing hormone in rats. J Pharmacol Exp Ther 238: 232-238 | en_US |
dc.identifier.citedreference | Mc Khann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. (1984) The clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group. Neurology 34: 939-944 | en_US |
dc.identifier.citedreference | Mellow A.M., Sunderland T., Cohen R.M., Lawlor B.A., Hill J.L., Newhouse P.A., Cohen M.R., Murphy D.L. (1989) Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology 98: 403-407 | en_US |
dc.identifier.citedreference | Metcalf G. (1982) Regulatory peptides as a source of new drugs: The clinical prospects for analogues of TRH which are resistant to metabolic degradation. Brain Res Rev 4: 389-408 | en_US |
dc.identifier.citedreference | Mewaldt S.P., Ghoneim M.M. (1979) The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 10: 205-210 | en_US |
dc.identifier.citedreference | Mitsumoto H., Salgado ED, Negroski D., Hanson M.R., Salanga V.D., Wilbur J.F., Wilbourn A.J., Breur A.C., Leatherman J. (1986) Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 36: 152-159 | en_US |
dc.identifier.citedreference | Mohs R.C., Davis B.N., Johns C.A., Mathe A.A., Greenwald B.S., Horvath T.B., Davis K.L. (1985) Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatr 142: 28-33 | en_US |
dc.identifier.citedreference | Molchan S.E., Mellow A.M., Lawlor B.A., Weingartner H.J., Cohen R.M., Cohen M.R., Sunderland T. (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100: 84-89 | en_US |
dc.identifier.citedreference | Narumi S., Nagai Y., Miyamoto M., Nagawa Y. (1983) Thyrotropin-releasing hormone (TRH) and its analogue (DN-1417): interaction with pentobarbital and choline uptake and acetylcholine synthesis of rat brain slices. Life Sci 32: 1637-1645 | en_US |
dc.identifier.citedreference | Nordberg A., Winblad B. (1981) Cholinergic receptors in human hippocampus—regional distribution and variance with age. Life Sci 29: 1937-1944 | en_US |
dc.identifier.citedreference | Okada M. (1991) Effects of a new thyrotropin releasing hormone analogue, YM-14673, on the in vivo release of acetylcholine as measured by intracerebral dialysis in rats. J Neurochem 56: 1544-1547 | en_US |
dc.identifier.citedreference | Okuda C., Mizobe T., Miyazaki M. (1987) The involvement of central cholinergic mechanisms in cardiovascular responses to intracerebroventricular and intravenous administration of thyrotropin-releasing hormone. Life Sci 40: 1293-1299 | en_US |
dc.identifier.citedreference | Pedigo N.W. (1988) Pharmacological adaptations and muscarinic receptor plasticity in hypothalamus of senescent rats treated chronically with cholinergic drugs. Psychopharmacology 95: 497-501 | en_US |
dc.identifier.citedreference | Perry E.K. (1980) The cholinergic system in old age and Alzheimer's disease. Age and Ageing 9: 1-8 | en_US |
dc.identifier.citedreference | Price D.L. (1986) New perspectives on Alzheimer's disease. Annu Rev Neurosci 9: 489-512 | en_US |
dc.identifier.citedreference | Reisberg B., Ferris S., De Leon M., Crook T. (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatr 139: 1136-1139 | en_US |
dc.identifier.citedreference | Rinne J.O. (1987) Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 404: 162-168 | en_US |
dc.identifier.citedreference | Safer D.J., Allen R.P. (1971) The central effects of scopolamine in man. Biol Psychiatr 3: 347-355 | en_US |
dc.identifier.citedreference | Schwarz R.D., Bernabei A.A., Spencer C.J., Pugsley T.A. (1990) Loss of muscarinic M1 receptors with aging in the cerebral cortex of Fisher 344 rats. Pharmacol Biochem Behav 35: 589-593 | en_US |
dc.identifier.citedreference | Sitaram N., Weingartner H., Gillin J.C. (1978) Human serial learning: enhancement with arecholine and choline and impairment with scopolamine. Science 201: 274-276 | en_US |
dc.identifier.citedreference | Sunderland T., Tariot P.N., Weingartner H., Murphy D.L., Newhouse P.A., Mueller E.A., Cohen R.M. (1986) Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatr 10: 599-610 | en_US |
dc.identifier.citedreference | Sunderland T., Tariot P.N., Cohen R.M., Weingartner H., Mueller E.A., Murphy D.L. (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatr 44: 418-426 | en_US |
dc.identifier.citedreference | Suzuki T., Fujimoto K., Oohata H., Kawashima K. (1989) Effects of TRH and DN-1417 on high potassium-evoked acetylcholine release from rat basal forebrain slices determined directly by radioimmunoassay. Gen Pharmacol 20: 239-242 | en_US |
dc.identifier.citedreference | Tariot P.N., Sunderland T., Weingartner H., Murphy D.L., Welkowitz J.A., Thompson K., Cohen R.M. (1987) Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 91: 489-495 | en_US |
dc.identifier.citedreference | Thompson J.M., Makino C.L., Whitaker J.R., Joseph J.A. (1984) Age-related decrease in apomorphine modulation of acetylcholine release from rat striatal slices. Brain Res 299: 169-173 | en_US |
dc.identifier.citedreference | van Kammen D.P., Murphy D.L. (1975) Attenuation of the euphoriant and activating effects of D- and L-amphetamine by lithium carbonate treatment. Psychopharmacologia 44: 215-224 | en_US |
dc.identifier.citedreference | Wechsler D. (1945) Standardized memory scale for clinical use. J Psychol 19: 87-95 | en_US |
dc.identifier.citedreference | Weingartner H., Grafman J., Boutelle W., Kaye W., Martin P.R. (1983) Forms of memory failure. Science 221: 380-382 | en_US |
dc.identifier.citedreference | Wenk G.L., Pierce D.J., Price D.L., Cork L.C. (1989) Age-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging 10: 11-19 | en_US |
dc.identifier.citedreference | Wesnes K., Warburton D.M. (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82: 147-150 | en_US |
dc.identifier.citedreference | White P., Goodhardt M.J., Keet J.P., Hiley C.R., Carasco L.H., Williams I.G., Bowen D.M. (1977) Neocortical cholinergic neurons in elderly people. Lancet i: 668-671 | en_US |
dc.identifier.citedreference | Whitehouse P.J., Au K.S. (1986) Cholinergic receptors in aging and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatr 10: 665-676 | en_US |
dc.identifier.citedreference | Winer B.J. (1981) Statistical principles in experimental design (2nd edition). Mc Graw-Hill, New York | en_US |
dc.identifier.citedreference | Winokur A., Beckman A.L. (1978) Effects of thyrotropin-releasing hormone, norepinephrine and acetylcholine on the activity of neurons in the hypothalamus, septum and cerebral cortex of the rat. Brain Res 150: 205-209 | en_US |
dc.identifier.citedreference | Wu C.F., Bertolli R., Sacconi M., Pepeu G., Consolo S. (1988) Decrease of brain acetylcholine release in freely-moving rats detected by microdialysis. Neurobiol Aging 9: 357-361 | en_US |
dc.identifier.citedreference | Yamamura M., Kinoshita K., Nakagawa H., Ishida R. (1991) Pharmacological study of TA-0910, a new thyrotropin-releasing hormone (TRH) analog: effects on experimental memory impairment in mice and rats. Jap J Pharmacol 55: 241-253 | en_US |
dc.identifier.citedreference | Yamazaki N., Nagaoka N., Nagawa Y. (1986) Effect of thyrotropin-releasing hormone and its analog DN-1417 on scopolamine-induced impairment of short-term memory in rats. Jap J Psychopharmacol 6: 359-366 | en_US |
dc.identifier.citedreference | Yarbrough G.G. (1979) On the neuropharmacology of thyrotropin releasing hormone (TRH). Prog Neurobiol 12: 291-312 | en_US |
dc.identifier.citedreference | Zornetzer S. (1986) The noradrenergic locus coeruleus and senescent memory dysfunction. In Crook T, Bartus R T, Ferris S, Gershon S (eds), Treatment development strategies for Alzheimer's disease. Mark Powley Assoc., Inc., Madison, CT, pp. 337-359 | en_US |
dc.identifier.citedreference | Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., Folstein M.F., Price D.L. (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24: 233-242 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.